22
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Epic as an Effective, Low Toxicity Salvage Therapy for Patients with Poor Risk Lymphoma Prior to Beam High Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation

, , , , , , , & show all
Pages 339-345 | Received 20 Feb 1999, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

N. C. McBride, J. D. Cavenagh, M. C. Ward, I. Grant, S. Schey, A. Gray, A. Hughes, M. J. Mills, P. Cervi, A. C. Newland & S. M. Kelsey. (2001) Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma. Leukemia & Lymphoma 42:1-2, pages 89-98.
Read now

Articles from other publishers (4)

Bongani Kaimila, Toon van der Gronde, Christopher Stanley, Edwards Kasonkanji, Maria Chikasema, Blessings Tewete, Paula Fox & Satish Gopal. (2017) Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi. Infectious Agents and Cancer 12:1.
Crossref
A Spencer, K Reed & C Arthur. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 0:0, pages 070602000936001-???.
Crossref
Kirit M. Ardeshna, Nicholaos Kakouros, Wendi Qian, Michael G. Powell, Nishaat Saini, Shirley D'Sa, Stephen Mackinnon, Peter J. Hoskin, Anthony H. Goldstone & David C. Linch. (2005) Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British Journal of Haematology 130:3, pages 363-372.
Crossref
K van Besien, A Rodriguez, S Tomany, A Younes, M Donato, A Sarris, S Giralt, R Mehra, B Andersson, J Gajewski, R Champlin & F Cabanillas. (2001) Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplantation 27:4, pages 397-404.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.